Nevro's AI-Powered Spinal Cord Stimulation System Receives CE Mark Certification, Expanding Global Reach

Nevro's HFX iQ: A Breakthrough in AI-Powered Pain Management

Nevro Corp. (NYSE: NVRO), a global medical device company, has achieved a significant milestone with the CE Mark Certification for its HFX iQ™ spinal cord stimulation (SCS) system in Europe 1

1

2

2

. This certification allows Nevro to market the device in all countries recognizing this standard, marking a crucial step in the company's global expansion strategy.

Revolutionary AI-Driven Technology

The HFX iQ system stands out as the first and only SCS system incorporating artificial intelligence (AI) technology. It combines high-frequency (10 kHz) therapy with cloud data insights to deliver personalized pain relief 1

1

2

2

. This innovative approach leverages over a decade of outcomes and real-world patient data, setting new standards in chronic pain management.

Key Features and Advantages

HFX iQ offers several unique advantages:

1. Personalized Treatment: The system uses the HFX Algorithm™, built from over 20 million data points and 80,000 implanted patients, to start patients on the most effective pain relief program 1

   1

   2

   2

   .

2. Comprehensive Data Integration: It combines clinical inputs like pain relief scores with Quality of Life factors such as medication usage and activity levels 1

   1

   2

   2

   .

3. Wide Frequency Range: HFX iQ can program both low frequency and Nevro's proprietary 10 kHz Therapy, offering the broadest range of frequencies in the market 1

   1

   2

   2

   .

4. Real-Time Adjustments: With a Bluetooth®-enabled Implantable Pulse Generator (IPG), patients can input assessments via smartphone and receive immediate programming adjustments 1

   1

   2

   2

   .

Expert Opinions and Clinical Impact

Dr. Ganesan Baranidharan from Leeds Teaching Hospital NHS Trust highlights the system's potential to optimize healthcare resources by reducing in-person programming and unnecessary hospital visits 2

2

. Prof. Faycal El Majdoub of Cologne-Merheim Medical Center emphasizes how HFX iQ empowers patients in their pain relief journey, potentially reducing dependence on clinical interventions 1

1

2

2

.

Market Implications and Company Performance

The CE Mark Certification is expected to drive Nevro's market penetration in Europe. The company plans to launch HFX iQ in select European countries starting in the first quarter of 2025 1

1

2

2

. This development has positively impacted Nevro's stock performance, with shares trading higher following the announcement 3

3

.

Financial Outlook

Nevro has revised its financial guidance for 2024:

• Revenue projection: $400 million to $405 million
• Adjusted EBITDA loss: Improved to $18 million-$16 million from previous $20 million-$18 million 3

  3

Broader Impact on Chronic Pain Management

The introduction of HFX iQ represents a significant advancement in the field of chronic pain management. By leveraging AI and data-driven approaches, it has the potential to transform patient care, offering more personalized and effective treatment options for those suffering from chronic pain conditions 1

1

2

2

3

3

.